Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Short Interest Up 327.4% in July

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) saw a significant growth in short interest in the month of July. As of July 31st, there was short interest totaling 65,538 shares, a growth of 327.4% from the July 15th total of 15,334 shares. Currently, 1.2% of the shares of the company are sold short. Based on an average daily volume of 638,720 shares, the short-interest ratio is currently 0.1 days.

Hedge Funds Weigh In On Neuphoria Therapeutics

A number of hedge funds have recently made changes to their positions in NEUP. Merck & Co. Inc. purchased a new position in Neuphoria Therapeutics in the 2nd quarter valued at approximately $43,818,000. Commonwealth Equity Services LLC purchased a new stake in shares of Neuphoria Therapeutics during the fourth quarter worth $43,000. XTX Topco Ltd purchased a new stake in shares of Neuphoria Therapeutics during the fourth quarter worth $47,000. Persistent Asset Partners Ltd raised its stake in shares of Neuphoria Therapeutics by 173.1% in the fourth quarter. Persistent Asset Partners Ltd now owns 13,403 shares of the company’s stock valued at $52,000 after acquiring an additional 8,495 shares in the last quarter. Finally, Boothbay Fund Management LLC acquired a new stake in shares of Neuphoria Therapeutics in the fourth quarter valued at $54,000. Hedge funds and other institutional investors own 15.90% of the company’s stock.

Neuphoria Therapeutics Stock Performance

Shares of NASDAQ:NEUP traded up $0.02 during midday trading on Wednesday, hitting $3.83. The company’s stock had a trading volume of 9,290 shares, compared to its average volume of 107,893. The business’s 50 day simple moving average is $3.97 and its 200 day simple moving average is $4.38. The company has a market cap of $20.68 million, a P/E ratio of -0.35 and a beta of 0.75. Neuphoria Therapeutics has a 12-month low of $3.19 and a 12-month high of $21.40.

Neuphoria Therapeutics (NASDAQ:NEUP) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.47. On average, sell-side analysts predict that Neuphoria Therapeutics will post -4.07 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on NEUP. Weiss Ratings reissued a “sell (d-)” rating on shares of Neuphoria Therapeutics in a report on Monday, June 1st. HC Wainwright cut shares of Neuphoria Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 15th. Finally, Wall Street Zen upgraded shares of Neuphoria Therapeutics to a “hold” rating in a research report on Saturday, July 25th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $21.00.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.